We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 226

Federal Circuit holds that even functional claims require structural fence posts

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • July 11 2014

In AbbVie Deutschland Gmbh v. Janssen Biotech, Inc., the Federal Circuit affirmed the district court decision that found AbbVie's patents directed to

Why are method of treatment claims and method of manufacture claims subject to scrutiny under the USPTO patent subject matter eligibility guidance?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • July 15 2014

The USPTO has asked for written comments on its patent subject matter eligibility guidance by July 31, 2014. In this article, I discuss why

Federal Circuit says Commission must toe the line in Invisalign ITC case

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • July 23 2014

In Align Technology, Inc. v. International Trade Commission, the Federal Circuit held that ITC action that violated ITC's own regulations warranted

Federal Circuit looks for a different kind of unexpected results in BMS v. Teva

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • July 2 2014

In Bristol-Myers Squibb Co. v. Teva Pharmaceuticals USA, Inc., the Federal Circuit affirmed the district court’s finding that BMS’s Baraclude patent

How the Supreme Court decision in Alice Corp. v. CLS Bank undermines the USPTO subject matter eligibility guidance

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • June 24 2014

On June 19, 2014, the Supreme Court issued its decision in Alice Corp. v. CLS Bank International, finding that patents directed to "a

Supreme Court to consider legal standard for patent indefiniteness

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 13 2014

On January 10, 2014, the U.S. Supreme Court granted certiorari in Nautilus Inc. v. Biosig Instruments, Inc., to review the legal standard for holding

Patent term adjustment - challenging applicant delays

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 22 2011

Hoffman-La Roche Inc. and Morphosys AG are among the latest patent holders to file a Patent Term Adjustment (PTA) action against the USPTO

USPTO issues new guidelines on subject matter eligibility under 35 USC 101 in view of Myriad and Prometheus

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 5 2014

The USPTO issued new guidelines for determining if claims are eligible for patenting in light of the Association for Molecular Pathology v. Myriad

Federal Circuit invalidates Prandin patent claim as obvious

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • June 27 2013

In its third look at the Novo Nordisk AS patent related to Prandin, in Novo Nordisk AS v. Caraco Pharmaceutical Laboratories Ltd., the Federal

Revisiting IDS guidlines? While you're at it . . .

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • June 3 2011

As I noted last week, the USPTO is revisiting its guidance on the Duty of Disclosure in the wake of the Federal Circuit's en banc decision in Therasense